PCSK9 and diabetes mellitus: Furthermore, these findings are consistent with the results of major outcome trials such as FOURIER and ODYSSEY OUTCOMES, which reported no significant increase in diabetes or neurocognitive adverse events with PCSK9 inhibitor therapy, even at very low LDL-C levels.